Profile
Sector:
IndustrialsIndustry:
Integrated Freight & LogisticsCountry:
United StatesIPO:
22 August 2005Website:
http://www.cryoportinc.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:05:52 GMTDividend
Analysts recommendations
Institutional Ownership
CYRX Latest News
Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell ™ Houston Facility NASHVILLE, Tenn. and HOUSTON , Oct. 22, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and Gulf Coast Regional Blood Center ("GCRBC"), a non-profit community blood center serving more than 26 counties throughout the state of Texas, today announced a strategic alliance to enhance the availability of high-quality, manufacture-ready cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment.
Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted Solutions for Secure IVF Specimen Management and Transport NASHVILLE, Tenn. and NEW YORK , Oct. 21, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and TMRW Life Sciences ("TMRW"), a fertility technology company offering the highest standard of care in offsite storage for frozen eggs, embryos and sperm in the U.S. with the only FDA-cleared automated specimen management and storage platform, today announced a strategic partnership to provide fertility clinics with complete solutions for secure specimen management and transport.
Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments NASHVILLE, Tenn. and CONROE, Texas , Oct. 15, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and VGXI, Inc., (VXGI) a subsidiary of GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) today announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments.
NASHVILLE, Tenn. and RANCHO CORDOVA, Calif.
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.42 per share a year ago.
What type of business is Cryoport?
CryoPort Inc is a provider of temperature-controlled supply chain solutions for the life sciences industry, offering a unique and evolving platform of critical products and solutions, including advanced packaging, informatics, specialized logistics services, biostorage services, and cryogenic equipment for the biological sciences. The company provides global solutions for the biopharmaceutical, animal health, and human reproductive medicine markets. Its main focus is on meeting the critical needs of the temperature-controlled supply chain in the biopharmaceutical space with an emphasis on servicing the rapidly growing cell and gene therapy market. Cryoport, Inc. was founded in 1999, and the company is headquartered in Brentwood, Tennessee.
What sector is Cryoport in?
Cryoport is in the Industrials sector
What industry is Cryoport in?
Cryoport is in the Integrated Freight & Logistics industry
What country is Cryoport from?
Cryoport is headquartered in United States
When did Cryoport go public?
Cryoport initial public offering (IPO) was on 22 August 2005
What is Cryoport website?
https://www.cryoportinc.com
Is Cryoport in the S&P 500?
No, Cryoport is not included in the S&P 500 index
Is Cryoport in the NASDAQ 100?
No, Cryoport is not included in the NASDAQ 100 index
Is Cryoport in the Dow Jones?
No, Cryoport is not included in the Dow Jones index
When was Cryoport the previous earnings report?
No data
When does Cryoport earnings report?
The next expected earnings date for Cryoport is 08 November 2024